Status:
COMPLETED
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
30-75 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects wit...
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current OHA (oral hypoglycaemic agent) treatment with stable dose for at least six months
- BMI (Body Mass Index) between 24 and 35 kg/m\^2 (both inclusive)
- Fasting plasma glucose between 6 and 15 mmol/l (both inclusive)
- Anti-GAD (glutamic acid decarboxylase) negative
Exclusion
- Known or suspected allergy to trial product or related products
- Receipt of any investigational drug within three months prior to this trial
- Recurrent severe hypoglycaemia as judged by the investigator
- Cardiac disease or any clinically significant abnormal ECG (electrocardiogram)
- Use of any drug (except oral hypoglycaemic agents (OHAs)) which in the investigator's opinion could interfere
- with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides)
- Liver or renal disease
Key Trial Info
Start Date :
September 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 1999
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01507311
Start Date
September 1 1999
End Date
December 1 1999
Last Update
January 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Århus C, Denmark, 8000